BPC-157 + TB-500 (10mg Blend) Dosage Protocol
Soft-tissue repair blend — BPC-157 5mg + TB-500 5mg in one combined vial (1:1); the combination is not clinically validated.
Fixed ratio: BPC-157 5 mg : TB-500 5 mg — a 1:1 blend. Every withdrawal keeps that ratio, so the components cannot be dosed independently.
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers. Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →Mix & measure BPC-157 + TB-500 · 10 mg
BPC-157 + TB-500 Dosage Chart: Per Day & Per Week
One practical dilution of the combined vial — the per-day dose in syringe units, and the per-week total it adds up to
Important: Start with the Prep & Injection Guide — it covers the preparation and safety basics every protocol on this site assumes.
Standard / Gradual Approach (3 mL = 3.33 mg/mL total blend)
Reconstitute: Add 3.0 mL bacteriostatic water to one 10 mg blend vial → final concentration 3.33 mg/mL total (1.67 mg/mL of each peptide).
Typical daily range: 600–1000 mcg total blend once daily (300–500 mcg of each peptide), over an 8–12 week course. One draw delivers a 1:1 BPC:TB-500 split.
Easy measuring: At 3.33 mg/mL, 1 unit = 33.3 mcg total (16.67 mcg of each peptide) on a U-100 syringe. The 3.0 mL dilution keeps every dose at 18 units or more for accurate measuring.
Storage: Lyophilized: store at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F) and do not freeze the mixed solution.
Per week. At one injection per day, 600 mcg/day is 4.2 mg of blend per week (2.1 mg BPC-157 + 2.1 mg TB-500) and 800 mcg/day is 5.6 mg per week (2.8 mg of each). On that basis a 10 mg vial reconstituted in 3 mL covers roughly 16 days at 600 mcg or 12 days at 800 mcg — about 16 draws of 0.18 mL. These are reference figures from documented research protocols, not a dosing recommendation.
Advanced / Aggressive Approach (Acute-Injury Support)
For acute soft-tissue research scenarios, some protocols front-load a higher dose for the first four weeks before tapering to maintenance. Robust human dose-finding data do not exist for this blend; use with caution.
The only combined-use human data is a small, low-quality intra-articular case series at higher, different-route doses[8] — it does not validate this subcutaneous blend. Treatment is generally limited to 8–12 weeks before cycling off to evaluate response.
Why BPC-157 + TB-500 draws research interest
These are the directions researchers and the peptide community most often explore BPC-157 + TB-500 for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
Soft-tissue & injury repair
The primary reason this blend is sought; both peptides are studied in animal models of tendon, ligament and muscle healing.
Inflammation modulation
Investigated in preclinical research for effects on inflammatory pathways around tissue injury; animal-only, not clinically validated.
Gut & GI protection
BPC-157 is explored in rodent studies of gut-lining and ulcer healing; investigational, with no approved human indication.
Angiogenesis & recovery
Researched in animal models for new blood-vessel formation thought to support recovery; preclinical evidence only.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Frequency: one subcutaneous injection each day for 8–12 weeks (optionally extended to 16). Because the vial is co-formulated 1:1, every dose drawn delivers an equal split of BPC-157 and TB-500. These figures come from reference protocols, not from approved human dosing — the combination itself is not clinically validated.
Reconstitution Steps
Draw 3.0 mL of bacteriostatic water into a sterile syringe.
Release it slowly down the vial’s inner wall to limit foaming.
Swirl or roll gently until fully dissolved — don’t shake.
Label with the date and concentration, then refrigerate at 2–8 °C (35.6–46.4 °F), shielded from light.
The 3.0 mL dilution keeps each dose at 18 units or more, where U-100 syringe markings are most precise. Avoid freezing the reconstituted solution, since freeze–thaw can denature the peptide.
Supplies Needed
Quantities below assume an 8–16 week course of once-daily injections with phased dosing (averaging ~700 mcg total blend per day across the cycle).
One 10 mg blend vial covers roughly two weeks at the averaged ~700 mcg/day, so plan about one vial every two weeks.
- 8 weeks: ~4 vials
- 12 weeks: ~6 vials
- 16 weeks: ~8 vials
- Per injection: 1 syringe
- 8 weeks (once daily): ~56 syringes
- 16 weeks (once daily): ~112 syringes
Use ~3.0 mL per 10 mg blend vial for reconstitution.
- 8 weeks (4 vials): ~12 mL → 2 bottles
- 16 weeks (8 vials): ~24 mL → 3 bottles
One for the vial stopper + one for the injection site each day.
- Per injection: 2 swabs
- 8 weeks (once daily): ~112 swabs → 1–2 boxes
Dosing Protocol
A suggested daily titration approach based on common reference doses.
- ▪Cycle Length: Typically 8–12 weeks; optional extension to ~16 weeks.
- ▪Timing: Inject at a consistent time each day and rotate injection sites systematically. Each draw delivers a 1:1 BPC:TB-500 ratio.
Storage Instructions
Correct storage is what preserves the peptide’s stability and activity.
- ▪Lyophilized: Hold the dry vial at −20 °C (−4 °F) in dry, dark conditions and limit moisture exposure[7].
- ▪Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F) and use within about 28 days; do not freeze the mixed solution, as freezing can denature peptides[8].
- ▪Handling: Let frozen vials warm to room temperature before opening so condensation won’t form, and keep the solution clear of heat and direct light.
- ▪Freeze–thaw: Avoid repeated freeze–thaw cycles of the reconstituted solution.
Important Notes
Practical points that keep daily administration safe and consistent.
Further reading: the full BPC-157 + TB-500 protocol and cycle guide covers how much per dose, how often and how long a cycle runs, and BPC-157 vs TB-500 sets out what each peptide is actually studied for before they are combined.
- ▪Sterile technique: Use a fresh sterile U-100 insulin syringe each time and drop it straight into a puncture-proof sharps container afterward.
- ▪Site rotation: Move between abdomen, thighs and upper arms to reduce local irritation and lipohypertrophy[9].
- ▪Slow injection: Push the plunger slowly and pause a few seconds before withdrawing the needle to prevent backflow.
- ▪Recordkeeping: Log the daily dose, injection site and any observations to keep the protocol consistent.
- ▪Regulatory note: Both BPC-157 and TB-500 are prohibited by WADA for athletic use and are not FDA-approved for human administration; eligibility for compounding (regulatory status remains in flux through 2026) is not the same as approval[10].
How This Works
This is a single co-formulated vial holding two unrelated research peptides at a fixed 1:1 ratio — 5 mg of each, 10 mg total.
BPC-157 is a stable 15-amino-acid peptide derived from a human gastric protein. In preclinical models it has been associated with cytoprotection, modulation of nitric-oxide pathways and angiogenesis, with reported activity across gastrointestinal, musculoskeletal and other tissues[1][2].
TB-500 is a synthetic fragment of Thymosin Beta-4 whose core proposed action is the sequestering of G-actin to regulate actin polymerization — the process behind cell migration in wound healing — and which has been linked preclinically to angiogenesis and reduced inflammation[3][4].
The rationale for combining them is complementary mechanisms: BPC-157 for trophic and anti-inflammatory effects, TB-500 for cell migration and angiogenesis[8]. This rationale is theoretical.
Important caveat: the combination is not clinically validated. The only combined-use human data is a small, low-quality intra-articular case series at higher, different-route doses — not this subcutaneous blend. Musculoskeletal “recovery” claims rest on animal data and anecdote and should be read as hypotheses.
Neither peptide is an approved medicine. Both are unapproved research chemicals presented here for research and educational purposes only.
Lifestyle Factors
Habits that may support recovery alongside the protocol.
- ▪Nutrition: Keep protein intake adequate to give tissue repair the building blocks it needs.
- ▪Activity & rest: Pair appropriate movement with real recovery time and avoid overtraining during an injury-recovery phase.
- ▪Sleep: Aim for 7–9 hours to support the body’s natural repair processes.
- ▪Stress: Manage stress with evidence-based practices, since it influences overall healing.
Potential Benefits & Side Effects
What preclinical and veterinary literature describe; human evidence is limited and individual results vary.
Potential Benefits
- ▪Soft-tissue repair (preclinical): Animal studies of the individual peptides report faster wound healing via enhanced angiogenesis and cell migration[5][6].
- ▪Inflammation & cytoprotection (preclinical): BPC-157 shows gastroprotective and anti-inflammatory effects, and thymosin pathways are linked to reduced inflammation, in animal models[11].
- ▪Tolerability (veterinary): Generally well tolerated in veterinary studies, with occasional mild injection-site reactions.
- ▪Note on humans: These benefits are not established in humans, and the BPC-157 + TB-500 combination is not clinically validated — no controlled trials of this blend have been completed[13].
Common Side Effects
- ▪Injection-site reactions: Mild redness, tenderness or soreness can occur; rotating sites helps.
- ▪Unknown long-term profile: Human safety data is limited, so caution and monitoring are advised.
- ▪Sport restriction: Both BPC-157 and TB-500 are WADA-prohibited substances for athletes.
Injection Technique
General subcutaneous technique, following established clinical best-practice guidance[14][15].
Pre-Injection Preparation
- ▪Wash your hands well with soap and water.
- ▪Wipe the vial stopper with an alcohol swab and let it air-dry.
- ▪Choose a site (abdomen, thigh, or upper arm) and clean it with a fresh alcohol swab, letting it dry fully[15].
- ▪Draw the intended dose, then check for air bubbles and push any out.
Injection Procedure
- ▪Pinch a skinfold at the chosen site between thumb and forefinger.
- ▪Insert the needle into the pinch at a 45–90-degree angle (use 45 degrees if the fat layer is thin)[14].
- ▪Skip aspiration for subcutaneous shots — it isn’t needed[14].
- ▪Press the plunger slowly and steadily until it’s fully down.
- ▪Wait 5–10 seconds, then pull the needle straight out to prevent leakage.
Post-Injection Care
- ▪Drop the used syringe straight into a puncture-proof sharps container — never recap a needle.
- ▪Return the reconstituted vial to the fridge right away.
- ▪Rotate the injection site each day to prevent irritation and lipohypertrophy[9].
- ▪Watch the site for excess redness, swelling, or signs of infection.
Recommended Source
For high-purity research peptides, we point researchers to Prime Lab Peptides for the BPC-157 + TB-500 (5 mg + 5 mg) blend vial.
Why Prime Lab Peptides?
- ▪Top-rated on Trustpilot: Independently reviewed as the highest-rated peptide lab on Trustpilot — making it the best current source in the USA.
- ▪Third-party tested: Every batch ships with a Certificate of Analysis (COA) confirming purity and composition.
- ▪Consistent quality: ISO-aligned manufacturing and handling keep product integrity reliable batch to batch.
- ▪Cold-chain integrity: Temperature-controlled shipping and storage across the whole fulfilment chain.
- ▪Research-grade purity: Fit for educational and research use that demands high-quality peptides.
Note: Product availability and specifications subject to change. Verify current product details on supplier website.
References
- 1
Journal of Physiology & PharmacologyBPC-157 (Body Protection Compound): pentadecapeptide from gastric juice with cytoprotective and wound-healing activity in preclinical models.
- 2
Journal of Chromatography A (PubMed)Doping-control analysis of TB-500 as a synthetic thymosin beta-4 fragment in biological samples.
- 3
WADA Scientific ResearchInvestigation of TB-500 metabolism, synthesis of its metabolites, and detection limits.
- 4
Racing Medication & Testing ConsortiumThymosin beta-4 regulatory bulletin covering TB-500 use in equine sports medicine.
- 5
Journal of Investigative Dermatology (PubMed)Thymosin beta-4 accelerates wound healing in a preclinical model.
- 6
FASEB Journal (PubMed)Active-site mapping of thymosin beta-4 fragments for angiogenesis and cell migration.
- 7
Peptide Storage GuideBest practices for storing lyophilized peptides (temperature, humidity and light protection).
- 8
BPC-157 + TB-500 Case Series (PubMed)Small, low-quality case series of combined BPC-157 and TB-500 for joint injury at higher, intra-articular doses; not a controlled trial.
- 9
NCBI BookshelfBest practices for subcutaneous injection: aseptic technique and site rotation.
- 10
WADA Prohibited ListClassification of TB-500 as a prohibited substance in competitive sport.
- 11
Journal of Investigative DermatologyThymosin beta-4 wound-healing mechanisms: collagen deposition, angiogenesis and granulation tissue.
- 12
Journal of Chromatography B (PubMed)Quantification of TB-500 metabolites and screening of wound-healing activity (prodrug hypothesis).
- 13
ClinicalTrials.govTrial registry for full-length thymosin beta-4 (e.g., dermal and ocular indications); no completed efficacy trials of the TB-500 fragment.
- 14
Centers for Disease Control and Prevention (CDC)Subcutaneous injection technique: angle, site and no-aspiration guidance.
- 15
Subcutaneous Injection Technique (Patient Education)How to administer a subcutaneous injection: clinical technique guidelines.
- 16
Prime Lab PeptidesTB-500 (5 mg) product page — purity specifications and certificates of analysis.
BPC-157 + TB-500 — frequently asked questions
How do I reconstitute a 10 mg vial of BPC-157 + TB-500?
Wipe the stopper with an alcohol swab, then inject your bacteriostatic water slowly down the inside wall of the vial. Let it sit and gently swirl until dissolved — never shake. Store the mixed vial in the refrigerator and draw doses with an insulin syringe. Use the calculator above to turn any dose into syringe units.
How much bacteriostatic water should I add to BPC-157 + TB-500?
There is no single correct amount — more water simply spreads the same 10 mg of peptide across a larger volume, which makes small doses easier to measure accurately. 1 to 3 mL per vial is typical. Enter your chosen volume in the calculator above to see the resulting concentration and syringe units.
What do the "units" on an insulin syringe mean?
On a U-100 insulin syringe, 100 units equal 1 mL, so 1 unit equals 0.01 mL. The calculator above converts your draw volume into these units automatically so you can measure without doing the math by hand.
How should I store BPC-157 + TB-500 after mixing?
Keep the reconstituted vial refrigerated at roughly 2 to 8 degrees Celsius, away from light, and avoid freezing it. Reconstituted research peptides are generally used within a few weeks. Always follow the specific guidance supplied with your product.
How many doses does a 10 mg vial of BPC-157 + TB-500 provide?
Divide the vial strength of 10 mg by the amount you use per injection. The calculator above reports this as "doses per vial" the moment you enter a dose.
Is BPC-157 + TB-500 approved for human use?
No. BPC-157 + TB-500 is sold strictly for laboratory and research purposes and is not approved by the FDA or other regulators for human use. Everything on this page is research information, not medical advice — consult a licensed healthcare professional before any use.
New protocols & dosing updates
Reconstitution charts, new peptide protocols and safety updates — straight to your inbox. No spam, unsubscribe anytime.